

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

- | | |
|----|--|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|----|--|

Comments were received at consultation which stated that there was often variation in accessing NICE approved treatments according to geographical area.
--

- | | |
|----|--|
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|----|--|

The committee would need to be aware of this variation.

- | | |
|----|---|
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
|----|---|

No

- | | |
|----|---|
| 4. | Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made? |
|----|---|

No additional stakeholders were identified.

Approved by Associate Director (name): Nicole Elliott

Date: 26.06.2019